News & Media

Read and download below our recent news and media releases


Endo-PAT system may help measure cardiovascular risk from breast cancer treatment

Itamar Medical - Head Office, 8 January 2017
SAN ANTONIO — The Endo-PAT2000 assay may be a simple way to measure vascular elasticity in outpatients after treatment with aromatase inhibitors, Douglas Yee, MD, director of the Masonic Cancer Center, professor of medicine and pharmacology at the University of Minnesota, and a HemOnc Today Editorial Board member, told HemOnc Today at the San Antonio Breast Cancer Symposium. more

FDA Clears Expanded Indication for Itamar Medical's WatchPAT Sleep Apnea Diagnostic Device for Adolescents

Itamar Medical - Head Office, 27 July 2016

Itamar Medical Reports Success in Clinical Study Validating WatchPAT for Central Sleep Apnea Differentiation, Submits Application for FDA Clearance of New WatchPAT Version

Itamar Medical - Head Office, 9 June 2016

Itamar Medical Offers a Total Sleep Apnea Management Solution to Cardiologists

Itamar Medical - Head Office, 13 May, 2015

Marketing Bulletin: Canada Youth WatchPAT

Itamar Medical - Head Office, 12 April 2016

EndoPAT distributor in China - Important Notice

Itamar Medical - Head Office, 26 April 2015
NEW EndoPAT exclusive distributor for the Chinese market.

Itamar Medical Launches WatchPAT Unified

Itamar Medical - Head Office, 09 June 2014
Click here to view Press Release

Itamar Medical's EndoPAT Featured on the Doctor's Channel

Itamar Medical - Head Office, 02 Mar 2014
Gilad Glick, CEO, Itamar Medical, introduces the Endopat 2000, an innovative device that can assess cardiac health in 15 minutes. more